Independent, head-to-head study shows significant health benefits of early fortification associated with Prolacta Bioscience’s 100% human milk-based fortifiers compared to cow milk-based fortifiers for premature infants
Type: Press Releases
Topic(s): Clinical Studies Clinical Studies on Prolact/Humavant CR Early Fortification
Should human milk-based nutritional products for premature infants be homogenized? More research is needed, new journal article says
Type: Press Releases
Topic(s): Clinical Studies on Prolact/Humavant CR Company Pasteurization Product
The story of baby Eliza and Octavia, as told by their mom, Caytlin
Type: Parent Stories
Topic(s): 28-32 weeks (very premature) Parents
The story of baby Aria, as told by her mom, Mya
Type: Parent Stories
Topic(s): 22-27 weeks (extremely premature) Parents
The story of baby Pierce, as told by his mom, Annelise
Type: Parent Stories
Topic(s): 22-27 weeks (extremely premature) Parents
The story of baby Parker, as told by his mom, Sarah
Type: Parent Stories
Topic(s): 28-32 weeks (very premature)
Prolacta Bioscience begins testing its breast milk-based products for use in Japan
Type: Prolacta in the News
Topic(s): Company
Human Milk Introduced to Japanese Market
Type: Prolacta in the News
Topic(s): Clinical Studies Company Growth
Prolacta Bioscience enrolls first infant in Japan-based clinical trial to evaluate the effect of an Exclusive Human Milk Diet on growth and safety in premature infants
Type: Press Releases
Topic(s): Clinical Studies
Not finding the reference you’re looking for?
Email us at info@prolacta.com
